Our cookies

We use cookies, which are small text files, to improve your experience on our website.
You can allow or reject non essential cookies or manage them individually.

Manage cookiesAllow all

Cookie policy

Our cookies

Allow all

We use cookies, which are small text files, to improve your experience on our website. You can allow all or manage them individually.

You can find out more on our cookie page at any time.

EssentialThese cookies are needed for essential functions such as logging in and making payments. Standard cookies can't be switched off and they don't store any of your information.
AnalyticsThese cookies help us collect information such as how many people are using our site or which pages are popular to help us improve customer experience. Switching off these cookies will reduce our ability to gather information to improve the experience.
FunctionalThese cookies are related to features that make your experience better. They enable basic functions such as social media sharing. Switching off these cookies will mean that areas of our website can't work properly.
AdvertisingThese cookies help us to learn what you're interested in so we can show you relevant adverts on other websites and track the effectiveness of our advertising.
PersonalisationThese cookies help us to learn what you're interested in so we can show you relevant content.

Save preferences

A new cholesterol busting drug hits the headlines

 A new cholesterol busting drug hits the headlines

A new cholesterol busting drug hit the headlines last week. It all sounds very exciting and I was on the radio and in the newspapers sharing HEART UK’s excitement and enthusiastic about the potential for a new way to lower cholesterol.

The medicine isn’t yet available on the NHS and has yet to go through the formal approval necessary to make sure that it is safe and indeed offers good value for the taxpayer. Similar cholesterol lowering medicines such as PCSK9i are also injected, rather than a tablet like statins but only available under certain criteria set out by the regulatory body NICE. What we don’t yet know is if this similar medicine will only be available in certain circumstances, such as if someone has had a heart-attack and can’t lower their cholesterol or they have FH. It would be highly unusual that this new medicine would be offered to people rather than a statin, which is the usual and most effective first medication option.

Other similar injectable medicines are only available from specialist clinics, such as lipid clinics and not prescribed by GPs so it will be interesting to see the detail which goes far beyond the headlines we all read last week.